CML Patients Approach Normal Life Expectancy With Imatinib Treatment
Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study. (Source: CancerNetwork)
Source: CancerNetwork - July 21, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Novartis unit Alcon posts modest Q2 gain
(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today.
The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss.
Novartis has been reviewing Alcon for a possible disposal, with an update slated for this year. All options are under consideration, Jimenez reiterated tod...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Optical/Ophthalmic Wall Street Beat Alcon Novartis Source Type: news
Survival in Imatinib-Treated CML Independent of Response Time Survival in Imatinib-Treated CML Independent of Response Time
The 10-year survival analysis shows no significant difference in outcomes based on imatinib regimen, including higher dose that has previously been linked to a faster response.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Dasatinib in Children: An Effective Alternative to Imatinib Dasatinib in Children: An Effective Alternative to Imatinib
In children and adolescents with chronic-phase chronic myeloid leukemia, dasatinib shows response rates and safety similar to those seen in adults.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Cancer Drug Imatinib May Slow New-Onset Type 1 Diabetes Cancer Drug Imatinib May Slow New-Onset Type 1 Diabetes
"This could one day be a treatment for type 1 diabetes, but this remains very early days," says the researcher.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Jorge E. Cortes, MD Tags: Conferences/ASCO Hematology Chronic Myeloid Leukemia News Videos Hematologic Malignancies Source Type: news
Dasatinib excels in worldwide phase II trial against pediatric CML
(University of Colorado Anschutz Medical Campus) Worldwide phase II clinical trial results presented ASCO 2017 show the promise of the second-generation drug dasatinib against pediatric CML. Of 113 pediatric patients studied, 75 percent of patients who had previously failed or did not tolerate imatinib saw progression-free survival 48 months after starting treatment with dasatinib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 5, 2017 Category: International Medicine & Public Health Source Type: news
KIT Inhibition by Imatinib Helps Severe Refractory Asthma
Improvement in airway hyperresponsiveness seen with imatinib versus placebo (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 22, 2017 Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Allergy, Emergency Medicine, Nursing, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news
Could Cancer Drug Gleevec Help With Severe Asthma?
Title: Could Cancer Drug Gleevec Help With Severe Asthma?Category: Health NewsCreated: 5/19/2017 12:00:00 AMLast Editorial Review: 5/22/2017 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - May 22, 2017 Category: Respiratory Medicine Source Type: news
Cancer drug Gleevec may help with severe asthma
A leukemia drug might also effectively treat severe asthma, a small-scale clinical trial suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 19, 2017 Category: Consumer Health News Source Type: news
Could Cancer Drug Gleevec Help With Severe Asthma?
A leukemia drug might also effectively treat severe asthma, a small-scale clinical trial suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 19, 2017 Category: Consumer Health News Source Type: news
Could Cancer Drug Gleevec Help With Severe Asthma?
Small study suggests a new approach might one day help those with uncontrolled lung disease (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 19, 2017 Category: Respiratory Medicine Tags: Nursing, Oncology, Pharmacy, Pulmonology, Asthma, Research, News, Source Type: news
Could Cancer Drug Gleevec Help with Severe Asthma?
Small study suggests a new approach might one day help those with uncontrolled lung disease Source: HealthDay Related MedlinePlus Pages: Asthma, Leukemia, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 19, 2017 Category: Consumer Health News Source Type: news
Could Cancer Drug Gleevec Help With Severe Asthma?
FRIDAY, May 19, 2017 -- A leukemia drug might also effectively treat severe asthma, a small-scale clinical trial suggests.
Gleevec (imatinib) reduced the " twitchiness " of airways, making them less likely to reflexively constrict when exposed to an... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 19, 2017 Category: General Medicine Source Type: news
Proof-of principle study finds imatinib improves symptoms for patients with severe asthma
In a new, proof-of-principle study researchers have found that targeting the mast cells with imatinib, a drug used to effectively treat certain forms of cancer, improved airway hyperresponsiveness, a measure of the sensitivity of the airway, and decreased the number of mast cells present in the airway. Treatment also produced a small improvement in airway function. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news
